Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The psychosis spectrum in Parkinson disease

Nature Reviews Neurology volume 13, pages 81–95 (2017)Cite this article

Subjects

Key Points

  • Parkinson disease (PD) psychosis refers to a spectrum of illusions, hallucinations and delusions that occur throughout the disease course

  • Evolving literature highlights the importance of recognizing and treating PD psychosis, and understanding its role as a clinical biomarker of disease stage, distribution and future progression

  • Current evidence points to PD psychosis as a set of symptoms with distinct pathophysiological mechanisms, as opposed to a single pathophysiological symptom with a spectrum of severity

  • The relationship between neuropathology in PD psychosis and in vivo measures of reduced metabolism, functional MRI alterations and cortical volume loss remains unclear

  • Further studies are needed to explore the role of PD medication in unmasking psychosis symptoms, why psychosis symptoms predict worse cognitive outcome, comparisons of psychosis symptoms and mechanisms in different clinical conditions, and development of novel treatments

Abstract

In 2007, the clinical and research profile of illusions, hallucinations, delusions and related symptoms in Parkinson disease (PD) was raised with the publication of a consensus definition of PD psychosis. Symptoms that were previously deemed benign and clinically insignificant were incorporated into a continuum of severity, leading to the rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. Here, we review this literature and the evolving view of PD psychosis. Key topics include the prospective risk of dementia in individuals with PD psychosis, and the causal and modifying effects of PD medication. We discuss recent developments, including recognition of an increase in the prevalence of psychosis with disease duration, addition of new visual symptoms to the psychosis continuum, and identification of frontal executive, visual perceptual and memory dysfunction at different disease stages. In addition, we highlight novel risk factors — for example, autonomic dysfunction — that have emerged from prospective studies, structural MRI evidence of frontal, parietal, occipital and hippocampal involvement, and approval of pimavanserin for the treatment of PD psychosis. The accumulating evidence raises novel questions and directions for future research to explore the clinical management and biomarker potential of PD psychosis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Regions of cortical atrophy in PD psychosis.

Similar content being viewed by others

References

  1. Ravina, B. et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov. Disord. 22, 1061–1068 (2007).

    PubMed  Google Scholar 

  2. Diederich, N. J., Fénelon, G., Stebbins, G. & Goetz, C. G. Hallucinations in Parkinson disease. Nat. Rev. Neurol. 5, 331–342 (2009).

    CAS  PubMed  Google Scholar 

  3. Fénelon, G. & Alves, G. Epidemiology of psychosis in Parkinson's disease. J. Neurol. Sci. 289, 12–17 (2010).

    PubMed  Google Scholar 

  4. Rabey, J. M. Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat. Disord. 15 (Suppl. 4), S105–S110 (2009).

    PubMed  Google Scholar 

  5. Friedman, J. H. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat. Disord. 16, 553–560 (2010).

    PubMed  Google Scholar 

  6. Friedman, J. H. Parkinson disease psychosis: update. Behav. Neurol. 27, 469–477 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Goetz, C. G. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov. Disord. 25 (Suppl. 1), S104–S109 (2010).

    PubMed  Google Scholar 

  8. Fénelon, G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr. 13, 18–25 (2008).

    PubMed  Google Scholar 

  9. Inzelberg, R., Kipervasser, S. & Korczyn, A. D. Auditory hallucinations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 64, 533–535 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Fénelon, G., Mahieux, F., Huon, R. & Ziegler, M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123, 733–745 (2000).

    PubMed  Google Scholar 

  11. Fénelon, G., Soulas, T., Cleret de Langavant, L., Trinkler, I. & Bachoud-Levi, A. C. Feeling of presence in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 82, 1219–1224 (2011).

    PubMed  PubMed Central  Google Scholar 

  12. Wood, R. A., Hopkins, S. A., Moodley, K. K. & Chan, D. Fifty percent prevalence of extracampine hallucinations in Parkinson's disease patients. Front. Neurol. 6, 263 (2015).

    PubMed  PubMed Central  Google Scholar 

  13. Boubert, L. & Barnes, J. Phenomenology of visual hallucinations and their relationship to cognitive profile in Parkinson's disease patients: preliminary observations. SAGE Open http://dx.doi.org/10.1177/2158244015585827 (2015).

  14. Goetz, C. G., Stebbins, G. T. & Ouyang, B. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov. Disord. 26, 2196–2200 (2011).

    PubMed  Google Scholar 

  15. Goetz, C. G., Fan, W., Leurgans, S., Bernard, B. & Stebbins, G. T. The malignant course of “benign hallucinations” in Parkinson disease. Arch. Neurol. 63, 713–716 (2006).

    PubMed  Google Scholar 

  16. Chou, K. L. et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin. Neuropharmacol. 28, 215–219 (2005).

    CAS  PubMed  Google Scholar 

  17. Papapetropoulos, S. et al. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol. 8, 21 (2008).

    PubMed  PubMed Central  Google Scholar 

  18. Factor, S. A. et al. Cognitive correlates of hallucinations and delusions in Parkinson's disease. J. Neurol. Sci. 347, 316–321 (2014).

    PubMed  Google Scholar 

  19. Moro, A., Munhoz, R. P., Moscovich, M., Arruda, W. O. & Teive, H. A. Delusional misidentification syndrome and other unusual delusions in advanced Parkinson's disease. Parkinsonism Relat. Disord. 19, 751–754 (2013).

    PubMed  Google Scholar 

  20. Pagonabarraga, J. et al. A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Mov. Disord. 23, 443–448 (2008).

    PubMed  Google Scholar 

  21. Ballard, C. et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am. J. Psychiatry 156, 1039–1045 (1999).

    CAS  PubMed  Google Scholar 

  22. Fernandez, H. H. et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov. Disord. 23, 484–500 (2008).

    PubMed  Google Scholar 

  23. Mosimann, U. P. et al. A semi-structured interview to assess visual hallucinations in older people. Int. J. Geriatr. Psychiatry 23, 712–718 (2008).

    PubMed  Google Scholar 

  24. Voss, T. et al. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism Relat. Disord. 19, 295–299 (2013).

    PubMed  Google Scholar 

  25. Yokoi, K. et al. Hallucinators find meaning in noises: pareidolic illusions in dementia with Lewy bodies. Neuropsychologia 56, 245–254 (2014).

    PubMed  Google Scholar 

  26. McKinlay, A. et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat. Disord. 14, 37–42 (2008).

    CAS  PubMed  Google Scholar 

  27. Fénelon, G., Soulas, T., Zenasni, F. & Cleret de Langavant, L. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS–NIMH criteria. Mov. Disord. 25, 763–766 (2010).

    PubMed  Google Scholar 

  28. Pagonabarraga, J. et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov. Disord. 31, 45–52 (2016).

    PubMed  Google Scholar 

  29. Friedman, J. H. Editorial on: Pagonabarraga, J. et al. Minor hallucinations occur in drug-naive Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; available from: DOI:10.1002/mds.26432. Mov. Disord. 31, 9–10 (2016).

    PubMed  Google Scholar 

  30. Mack, J. et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am. J. Geriatr. Psychiatry 20, 123–132 (2012).

    PubMed  PubMed Central  Google Scholar 

  31. Gibson, G. et al. Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4-year study. Int. J. Geriatr. Psychiatry 28, 626–631 (2013).

    CAS  PubMed  Google Scholar 

  32. de la Riva, P., Smith, K., Xie, S. X. & Weintraub, D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 83, 1096–1103 (2014).

    PubMed  PubMed Central  Google Scholar 

  33. Forsaa, E. B. et al. A 12-year population-based study of psychosis in Parkinson disease. Arch. Neurol. 67, 996–1001 (2010).

    PubMed  Google Scholar 

  34. Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. & Kragh-Sorensen, P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387–392 (2003).

    PubMed  Google Scholar 

  35. Anang, J. B. et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83, 1253–1260 (2014).

    PubMed  PubMed Central  Google Scholar 

  36. Uc, E. Y. et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 73, 1469–1477 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Morgante, L. et al. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J. Neurol. Neurosurg. Psychiatry 83, 76–82 (2012).

    PubMed  Google Scholar 

  38. Ibarretxe-Bilbao, N. et al. Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J. Neurol. Neurosurg. Psychiatry 81, 650–657 (2010).

    PubMed  Google Scholar 

  39. Ramirez-Ruiz, B., Junque, C., Marti, M. J., Valldeoriola, F. & Tolosa, E. Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement. Geriatr. Cogn. Disord. 23, 281–288 (2007).

    PubMed  Google Scholar 

  40. Gasca-Salas, C., Clavero, P., Garcia-Garcia, D., Obeso, J. A. & Rodriguez-Oroz, M. C. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment. Hum. Brain Mapp. 37, 968–977 (2016).

    PubMed  Google Scholar 

  41. Reijnders, J. S., Ehrt, U., Lousberg, R., Aarsland, D. & Leentjens, A. F. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat. Disord. 15, 379–382 (2009).

    CAS  PubMed  Google Scholar 

  42. Rana, A. Q., Vaid, H. M., Edun, A., Dogu, O. & Rana, M. A. Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson's disease. J. Neurol. Sci. 323, 158–161 (2012).

    PubMed  Google Scholar 

  43. Bodis-Wollner, I. Foveal vision is impaired in Parkinson's disease. Parkinsonism Relat. Disord. 19, 1–14 (2013).

    PubMed  Google Scholar 

  44. Lee, J. Y. et al. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's disease. Mov. Disord. 29, 61–67 (2014).

    PubMed  Google Scholar 

  45. Ramirez-Ruiz, B., Junque, C., Marti, M. J., Valldeoriola, F. & Tolosa, E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov. Disord. 21, 1483–1487 (2006).

    PubMed  Google Scholar 

  46. Shin, S. et al. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 83, 1155–1161 (2012).

    PubMed  Google Scholar 

  47. Barnes, J. & Boubert, L. Visual memory errors in Parkinson's disease patient with visual hallucinations. Int. J. Neurosci. 121, 159–164 (2011).

    CAS  PubMed  Google Scholar 

  48. Moustafa, A. A., Krishna, R., Frank, M. J., Eissa, A. M. & Hewedi, D. H. Cognitive correlates of psychosis in patients with Parkinson's disease. Cogn. Neuropsychiatry 19, 381–398 (2014).

    PubMed  Google Scholar 

  49. Ozer, F. et al. Cognitive impairment patterns in Parkinson's disease with visual hallucinations. J. Clin. Neurosci. 14, 742–746 (2007).

    PubMed  Google Scholar 

  50. Katzen, H. et al. Multi-modal hallucinations and cognitive function in Parkinson's disease. Dement. Geriatr. Cogn. Disord. 30, 51–56 (2010).

    PubMed  PubMed Central  Google Scholar 

  51. Koerts, J. et al. Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. Parkinsonism Relat. Disord. 16, 270–274 (2010).

    PubMed  Google Scholar 

  52. Llebaria, G. et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov. Disord. 25, 2785–2791 (2010).

    PubMed  Google Scholar 

  53. Poletti, M. et al. Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov. Disord. 27, 1679–1682 (2012).

    PubMed  Google Scholar 

  54. Harding, A. J., Broe, G. A. & Halliday, G. M. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125, 391–403 (2002).

    CAS  PubMed  Google Scholar 

  55. Gallagher, D. A. et al. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain 134, 3299–3309 (2011).

    PubMed  Google Scholar 

  56. Papapetropoulos, S., McCorquodale, D. S., Gonzalez, J., Jean-Gilles, L. & Mash, D. C. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat. Disord. 12, 253–256 (2006).

    PubMed  Google Scholar 

  57. Jacobson, S. A. et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat. Disord. 20, 1009–1014 (2014).

    PubMed  PubMed Central  Google Scholar 

  58. Kalaitzakis, M. E. et al. Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat. Disord. 15, 196–204 (2009).

    CAS  PubMed  Google Scholar 

  59. Harding, A. J., Stimson, E., Henderson, J. M. & Halliday, G. M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125, 2431–2445 (2002).

    PubMed  Google Scholar 

  60. Janzen, J. et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. J. Neurol. 259, 147–154 (2012).

    CAS  PubMed  Google Scholar 

  61. Oka, H. et al. Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations. Mov. Disord. 22, 1510–1514 (2007).

    PubMed  Google Scholar 

  62. Zhu, K., van Hilten, J. J., Putter, H. & Marinus, J. Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study. Mov. Disord. 28, 755–762 (2013).

    PubMed  Google Scholar 

  63. Lenka, A., Hegde, S., Jhunjhunwala, K. R. & Pal, P. K. Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: a review. Parkinsonism Relat. Disord. 22, 1–8 (2016).

    PubMed  Google Scholar 

  64. Meral, H. et al. Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease. Clin. Neurol. Neurosurg. 109, 862–867 (2007).

    PubMed  Google Scholar 

  65. Gama, R. L. et al. Risk factors for visual hallucinations in patients with Parkinson's disease. Neurol. Res. 37, 112–116 (2015).

    PubMed  Google Scholar 

  66. Hirayama, M. et al. Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 17, 46–49 (2011).

    PubMed  Google Scholar 

  67. Goetz, C. G. et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50, 515–517 (1998).

    CAS  PubMed  Google Scholar 

  68. Dotchin, C. L., Jusabani, A. & Walker, R. W. Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Parkinsonism Relat. Disord. 15, 457–460 (2009).

    CAS  PubMed  Google Scholar 

  69. Lenka, A., Arumugham, S. S., Christopher, R. & Pal, P. K. Genetic substrates of psychosis in patients with Parkinson's disease: a critical review. J. Neurol. Sci. 364, 33–41 (2016).

    PubMed  Google Scholar 

  70. Papapetropoulos, S. et al. Phenotypic associations of tau and ApoE in Parkinson's disease. Neurosci. Lett. 414, 141–144 (2007).

    CAS  PubMed  Google Scholar 

  71. Factor, S. A. et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov. Disord. 26, 2190–2195 (2011).

    PubMed  PubMed Central  Google Scholar 

  72. de la Fuente-Fernandez, R., Nunez, M. A. & Lopez, E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin. Neuropharmacol. 22, 226–230 (1999).

    CAS  PubMed  Google Scholar 

  73. Goetz, C. G. et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: case–control study. Arch. Neurol. 58, 209–213 (2001).

    CAS  PubMed  Google Scholar 

  74. Camicioli, R. et al. Apolipoprotein E ε4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov. Disord. 20, 989–994 (2005).

    PubMed  Google Scholar 

  75. Feldman, B., Chapman, J. & Korczyn, A. D. Apolipoprotein ε4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol. Scand. 113, 14–17 (2006).

    CAS  PubMed  Google Scholar 

  76. Monsell, S. E. et al. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism Relat. Disord. 20, 503–507 (2014).

    PubMed  PubMed Central  Google Scholar 

  77. Murray, P. S., Kumar, S., Demichele-Sweet, M. A. & Sweet, R. A. Psychosis in Alzheimer's disease. Biol. Psychiatry 75, 542–552 (2014).

    PubMed  Google Scholar 

  78. Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783–1794 (2009).

    PubMed  PubMed Central  Google Scholar 

  79. Oeda, T. et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol. Aging 36, 3306–3313 (2015).

    CAS  PubMed  Google Scholar 

  80. Li, Y. et al. Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiol. Aging 35, 935.e3–935.e8 (2014).

    CAS  Google Scholar 

  81. Winder-Rhodes, S. E. et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 136, 392–399 (2013).

    PubMed  Google Scholar 

  82. Creese, B. et al. Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. Am. J. Geriatr. Psychiatry 22, 580–586 (2014).

    PubMed  Google Scholar 

  83. Kiferle, L. et al. Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci. Lett. 422, 228–231 (2007).

    CAS  PubMed  Google Scholar 

  84. Andreassen, O. A. et al. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol. Psychiatry 20, 207–214 (2015).

    CAS  PubMed  Google Scholar 

  85. Desikan, R. S. et al. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol. Psychiatry 20, 1588–1595 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Nho, K. et al. Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults. J. Alzheimers Dis. 45, 1197–1206 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Onofrj, M. et al. Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. Behav. Neurol. 27, 479–493 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Diederich, N. J., Goetz, C. G. & Stebbins, G. T. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov. Disord. 20, 130–140 (2005).

    PubMed  Google Scholar 

  89. Collerton, D., Perry, E. & McKeith, I. Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav. Brain Sci. 28, 737–757 (2005).

    PubMed  Google Scholar 

  90. Shine, J. M., Halliday, G. M., Naismith, S. L. & Lewis, S. J. Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov. Disord. 26, 2154–2159 (2011).

    PubMed  Google Scholar 

  91. Shine, J. M., O'Callaghan, C., Halliday, G. M. & Lewis, S. J. Tricks of the mind: visual hallucinations as disorders of attention. Prog. Neurobiol. 116, 58–65 (2014).

    PubMed  Google Scholar 

  92. Muller, A. J., Shine, J. M., Halliday, G. M. & Lewis, S. J. Visual hallucinations in Parkinson's disease: theoretical models. Mov. Disord. 29, 1591–1598 (2014).

    PubMed  Google Scholar 

  93. Shine, J. M. et al. Imagine that: elevated sensory strength of mental imagery in individuals with Parkinson's disease and visual hallucinations. Proc. Biol. Sci. 282, 20142047 (2015).

    PubMed  PubMed Central  Google Scholar 

  94. Shine, J. M., Halliday, G. H., Carlos, M., Naismith, S. L. & Lewis, S. J. Investigating visual misperceptions in Parkinson's disease: a novel behavioral paradigm. Mov. Disord. 27, 500–505 (2012).

    PubMed  Google Scholar 

  95. Shine, J. M. et al. The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Hum. Brain Mapp. 35, 2206–2219 (2014).

    PubMed  Google Scholar 

  96. Yao, N. et al. The default mode network is disrupted in Parkinson's disease with visual hallucinations. Hum. Brain Mapp. 35, 5658–5666 (2014).

    PubMed  PubMed Central  Google Scholar 

  97. Botha, H. & Carr, J. Attention and visual dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 18, 742–747 (2012).

    PubMed  Google Scholar 

  98. Carter, R. & ffytche, D. H. On visual hallucinations and cortical networks: a trans-diagnostic review. J. Neurol. 262, 1780–1790 (2015).

    PubMed  PubMed Central  Google Scholar 

  99. Lenka, A., Jhunjhunwala, K. R., Saini, J. & Pal, P. K. Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: a critical review. Parkinsonism Relat. Disord. 21, 683–691 (2015).

    PubMed  Google Scholar 

  100. Ibarretxe-Bilbao, N., Junque, C., Marti, M. J. & Tolosa, E. Cerebral basis of visual hallucinations in Parkinson's disease: structural and functional MRI studies. J. Neurol. Sci. 310, 79–81 (2011).

    PubMed  Google Scholar 

  101. Goldman, J. G. et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain 137, 849–859 (2014).

    PubMed  PubMed Central  Google Scholar 

  102. Ramirez-Ruiz, B. et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur. J. Neurol. 14, 750–756 (2007).

    CAS  PubMed  Google Scholar 

  103. Watanabe, H. et al. Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination. Mov. Disord. 28, 1732–1736 (2013).

    PubMed  Google Scholar 

  104. Meppelink, A. M., de Jong, B. M., Teune, L. K. & van Laar, T. Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations. Mov. Disord. 26, 142–147 (2011).

    PubMed  Google Scholar 

  105. Pagonabarraga, J. et al. Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 20, 290–296 (2014).

    PubMed  Google Scholar 

  106. Ibarretxe-Bilbao, N. et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J. Neurol. 255, 1324–1331 (2008).

    PubMed  Google Scholar 

  107. Sanchez-Castaneda, C. et al. Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia. Mov. Disord. 25, 615–622 (2010).

    PubMed  Google Scholar 

  108. Gama, R. L. et al. Structural brain abnormalities in patients with Parkinson's disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn. 87, 97–103 (2014).

    PubMed  Google Scholar 

  109. Kraft, E., Winkelmann, J., Trenkwalder, C. & Auer, D. P. Visual hallucinations, white matter lesions and disease severity in Parkinson's disease. Acta Neurol. Scand. 99, 362–367 (1999).

    CAS  PubMed  Google Scholar 

  110. Zhong, J. et al. Why psychosis is frequently associated with Parkinson's disease? Neural Regen. Res. 8, 2548–2556 (2013).

    PubMed  PubMed Central  Google Scholar 

  111. Ravina, B. et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov. Disord. 27, 1392–1397 (2012).

    PubMed  PubMed Central  Google Scholar 

  112. Ballanger, B. et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 67, 416–421 (2010).

    PubMed  Google Scholar 

  113. Huot, P. et al. Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Mov. Disord. 27, 735–742 (2012).

    CAS  PubMed  Google Scholar 

  114. Minoshima, S. et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann. Neurol. 50, 358–365 (2001).

    CAS  PubMed  Google Scholar 

  115. Lobotesis, K. et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56, 643–649 (2001).

    CAS  PubMed  Google Scholar 

  116. Firbank, M. J., Lloyd, J. & O'Brien, J. T. The relationship between hallucinations and FDG-PET in dementia with Lewy bodies. Brain Imaging Behav. 10, 636–639 (2015).

    Google Scholar 

  117. Boecker, H. et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch. Neurol. 64, 984–988 (2007).

    PubMed  Google Scholar 

  118. Nagano-Saito, A. et al. Visual hallucination in Parkinson's disease with FDG PET. Mov. Disord. 19, 801–806 (2004).

    PubMed  Google Scholar 

  119. Park, H. K. et al. Visual hallucinations and cognitive impairment in Parkinson's disease. Can. J. Neurol. Sci. 40, 657–662 (2013).

    PubMed  Google Scholar 

  120. Okada, K., Suyama, N., Oguro, H., Yamaguchi, S. & Kobayashi, S. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J. Neurol. 246, 365–368 (1999).

    CAS  PubMed  Google Scholar 

  121. Oishi, N. et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65, 1708–1715 (2005).

    CAS  PubMed  Google Scholar 

  122. Goetz, C. G., Vaughan, C. L., Goldman, J. G. & Stebbins, G. T. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov. Disord. 29, 115–117 (2014).

    PubMed  Google Scholar 

  123. ffytche, D. H. The hodology of hallucinations. Cortex 44, 1067–1083 (2008).

    PubMed  Google Scholar 

  124. Kataoka, H., Furiya, Y., Morikawa, M., Ueno, S. & Inoue, M. Increased temporal blood flow associated with visual hallucinations in Parkinson's disease with dementia. Mov. Disord. 23, 464–465 (2008).

    PubMed  Google Scholar 

  125. Stebbins, G. T. et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 63, 1409–1416 (2004).

    CAS  PubMed  Google Scholar 

  126. Meppelink, A. M. et al. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 132, 2980–2993 (2009).

    PubMed  Google Scholar 

  127. Holroyd, S. & Wooten, G. F. Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. J. Neuropsychiatry Clin. Neurosci. 18, 402–404 (2006).

    PubMed  Google Scholar 

  128. Ramírez-Ruiz, B. et al. Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Mov. Disord. 23, 2335–2343 (2008).

    PubMed  Google Scholar 

  129. Yao, N. et al. Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations. Parkinsonism Relat. Disord. 21, 131–137 (2015).

    PubMed  Google Scholar 

  130. Matsui, H. et al. The relation between visual hallucinations and visual evoked potential in Parkinson disease. Clin. Neuropharmacol. 28, 79–82 (2005).

    PubMed  Google Scholar 

  131. Kurita, A., Murakami, M., Takagi, S., Matsushima, M. & Suzuki, M. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov. Disord. 25, 167–171 (2010).

    PubMed  Google Scholar 

  132. Onofrj, M. et al. Visual hallucinations in Parkinson's disease: clues to separate origins. J. Neurol. Sci. 248, 143–150 (2006).

    CAS  PubMed  Google Scholar 

  133. Onofrj, M. et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol. Sci. 23 (Suppl. 2), S91–S94 (2002).

    PubMed  Google Scholar 

  134. Manganelli, F. et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain 132, 2350–2355 (2009).

    PubMed  PubMed Central  Google Scholar 

  135. Seppi, K. et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), S42–S80 (2011).

    PubMed  PubMed Central  Google Scholar 

  136. Pollak, P. et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J. Neurol. Neurosurg. Psychiatry 75, 689–695 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  137. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340, 757–763 (1999).

  138. Wolters, E. C. et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40, 832–834 (1990).

    CAS  PubMed  Google Scholar 

  139. Ondo, W. G., Tintner, R., Voung, K. D., Lai, D. & Ringholz, G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord. 20, 958–963 (2005).

    PubMed  Google Scholar 

  140. Shotbolt, P., Samuel, M., Fox, C. & David, A. S. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr. Dis. Treat. 5, 327–332 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  141. Kurlan, R., Cummings, J., Raman, R., Thal, L. & Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68, 1356–1363 (2007).

    CAS  PubMed  Google Scholar 

  142. Ondo, W. G., Levy, J. K., Vuong, K. D., Hunter, C. & Jankovic, J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov. Disord. 17, 1031–1035 (2002).

    PubMed  Google Scholar 

  143. Goetz, C. G., Blasucci, L. M., Leurgans, S. & Pappert, E. J. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55, 789–794 (2000).

    CAS  PubMed  Google Scholar 

  144. Weintraub, D. et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 73, 535–541 (2016).

    PubMed  PubMed Central  Google Scholar 

  145. Ballard, C. et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J. Am. Med. Dir. Assoc. 16, 898.e1–898.e7 (2015).

    Google Scholar 

  146. Meltzer, H. Y. et al. Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 35, 881–892 (2010).

    CAS  PubMed  Google Scholar 

  147. Cummings, J. et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383, 533–540 (2014).

    CAS  PubMed  Google Scholar 

  148. Borgemeester, R. W., Lees, A. J. & van Laar, T. Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence. Parkinsonism Relat. Disord. 27, 35–40 (2016).

    PubMed  Google Scholar 

  149. van Laar, T., Postma, A. G. & Drent, M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism Relat. Disord. 16, 71–72 (2010).

    PubMed  Google Scholar 

  150. Geerligs, L., Meppelink, A. M., Brouwer, W. H. & van Laar, T. The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study. Clin. Neuropharmacol. 32, 266–268 (2009).

    CAS  PubMed  Google Scholar 

  151. Pietz, K., Hagell, P. & Odin, P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol. Neurosurg. Psychiatry 65, 709–716 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  152. Martinez-Martin, P. et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov. Disord. 30, 510–516 (2015).

    CAS  PubMed  Google Scholar 

  153. Todorova, A. & Ray Chaudhuri, K. Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 19, 1073–1078 (2013).

    PubMed  Google Scholar 

  154. Ueda, S., Koyama, K. & Okubo, Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J. ECT 26, 111–115 (2010).

    PubMed  Google Scholar 

  155. Usui, C. et al. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1704–1708 (2011).

    PubMed  Google Scholar 

  156. Chaudhuri, K. R. & Fung, V. S. Fast Facts: Parkinson's Disease 4th edn (Health Press Limited, 2016).

    Google Scholar 

  157. ffytche, D. H. Visual hallucinatory syndromes: past, present, and future. Dialogues Clin. Neurosci. 9, 173–189 (2007).

    PubMed  PubMed Central  Google Scholar 

  158. ffytche, D. H. Visual hallucinations in eye disease. Curr. Opin. Neurol. 22, 28–35 (2009).

    PubMed  Google Scholar 

  159. Ebersbach, G. An artist's view of drug-induced hallucinosis. Mov. Disord. 18, 833–834 (2003).

    PubMed  Google Scholar 

  160. Archibald, N. K., Clarke, M. P., Mosimann, U. P. & Burn, D. J. Visual symptoms in Parkinson's disease and Parkinson's disease dementia. Mov. Disord. 26, 2387–2395 (2011).

    PubMed  Google Scholar 

  161. Diederich, N. J., Stebbins, G., Schiltz, C. & Goetz, C. G. Are patients with Parkinson's disease blind to blindsight? Brain 137, 1838–1849 (2014).

    PubMed  PubMed Central  Google Scholar 

  162. Santhouse, A. M., Howard, R. J. & ffytche, D. H. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain 123, 2055–2064 (2000).

    PubMed  Google Scholar 

  163. Ettinger, U. et al. Decomposing the neural correlates of antisaccade eye movements using event-related FMRI. Cereb. Cortex 18, 1148–1159 (2008).

    PubMed  Google Scholar 

  164. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003).

    PubMed  Google Scholar 

  165. De Marco, E. V. et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov. Disord. 23, 460–463 (2008).

    PubMed  Google Scholar 

  166. Creese, B. et al. No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. Neurosci. Lett. 531, 1–4 (2012).

    CAS  PubMed  Google Scholar 

  167. Kaiser, R. et al. L-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60, 1750–1755 (2003).

    CAS  PubMed  Google Scholar 

  168. Wang, J., Zhao, C., Chen, B. & Liu, Z. L. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease. Neurosci. Lett. 355, 193–196 (2004).

    CAS  PubMed  Google Scholar 

  169. Schumacher-Schuh, A. F. et al. Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. Int. J. Neuropsychopharmacol. 16, 1251–1258 (2013).

    CAS  PubMed  Google Scholar 

  170. Makoff, A. J. et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 10, 43–48 (2000).

    CAS  PubMed  Google Scholar 

  171. Fujii, C. et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin. Genet. 56, 394–399 (1999).

    CAS  PubMed  Google Scholar 

  172. Wang, J., Si, Y. M., Liu, Z. L. & Yu, L. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. Pharmacogenetics 13, 365–369 (2003).

    CAS  PubMed  Google Scholar 

  173. Goldman, J. G., Goetz, C. G., Berry-Kravis, E., Leurgans, S. & Zhou, L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch. Neurol. 61, 1280–1284 (2004).

    PubMed  Google Scholar 

  174. Goldman, J. G. et al. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov. Disord. 26, 1781–1782 (2011).

    PubMed  PubMed Central  Google Scholar 

  175. Lin, J. J., Yueh, K. C., Lin, S. Z., Harn, H. J. & Liu, J. T. Genetic polymorphism of the angiotensin converting enzyme and l-dopa-induced adverse effects in Parkinson's disease. J. Neurol. Sci. 252, 130–134 (2007).

    CAS  PubMed  Google Scholar 

  176. Pascale, E. et al. Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson's disease and of l-dopa-induced adverse effects. J. Neurol. Sci. 276, 18–21 (2009).

    CAS  PubMed  Google Scholar 

  177. Schumacher-Schuh, A. F. et al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. Pharmacogenomics J. 14, 289–294 (2014).

    CAS  PubMed  Google Scholar 

  178. De Luca, V. et al. HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. Neuropsychobiology 59, 239–245 (2009).

    CAS  PubMed  Google Scholar 

  179. Nebe, A. & Ebersbach, G. Selective diplopia in Parkinson's disease: a special subtype of visual hallucination? Mov. Disord. 22, 1175–1178 (2007).

    PubMed  Google Scholar 

  180. Urwyler, P. et al. Visual complaints and visual hallucinations in Parkinson's disease. Parkinsonism Relat. Disord. 20, 318–322 (2014).

    PubMed  Google Scholar 

  181. Meppelink, A. M., Koerts, J., Borg, M., Leenders, K. L. & van Laar, T. Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Mov. Disord. 23, 1906–1912 (2008).

    PubMed  Google Scholar 

  182. Barnes, J. & Boubert, L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. J. Neurol. Neurosurg. Psychiatry 79, 190–192 (2008).

    CAS  PubMed  Google Scholar 

  183. Imamura, K., Wada-Isoe, K., Kitayama, M. & Nakashima, K. Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. Acta Neurol. Scand. 117, 255–259 (2008).

    CAS  PubMed  Google Scholar 

  184. Grossi, D. et al. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int. J. Geriatr. Psychiatry 20, 668–673 (2005).

    PubMed  Google Scholar 

  185. Chung, E. J., Seok, K. & Kim, S. J. A comparison of montreal cognitive assessment between patients with visual hallucinations and without visual hallucinations in Parkinson's disease. Clin. Neurol. Neurosurg. 130, 98–100 (2015).

    PubMed  Google Scholar 

  186. Breier, A. et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol. Psychiatry 52, 438–445 (2002).

    CAS  PubMed  Google Scholar 

  187. Burn, D. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov. Disord. 21, 1899–1907 (2006).

    PubMed  Google Scholar 

  188. Aarsland, D. et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8, 613–618 (2009).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Dr Michael Haworth for help in preparing the final manuscript, Dr Rowena Carter for help preparing Figure 1, and the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre and Dementia Unit and NIHR Programme Grants for Applied Research (SHAPED RP-PG-0610-10100) for supporting their involvement in this work. K.R.C. acknowledges support from the European Union, Parkinson's UK, the NIHR and the Parkinson's Disease Non Motor group. D.A. is a Royal Society Wolfson Research Merit Award Holder and thanks the Wolfson Foundation and the Royal Society for their support. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health.

Author information

Authors and Affiliations

  1. KCL-PARCOG group, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK

    Dominic H. ffytche, Byron Creese, Marios Politis, K. Ray Chaudhuri, Daniel Weintraub, Clive Ballard & Dag Aarsland

  2. Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK, De Crespigny Park, London, SE5 8AF, UK

    Dominic H. ffytche & Dag Aarsland

  3. University of Exeter Medical School, University of Exeter, EX1 2LU, UK

    Byron Creese & Clive Ballard

  4. Neurodegeneration Imaging Group, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 125 Coldharbour Lane, London, SE5 9NU, UK

    Marios Politis

  5. Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, National Parkinson Foundation Centre of Excellence, King's College London/Kings College Hospital, 5 Cutcombe Road, London, SE5 9RT, UK

    K. Ray Chaudhuri

  6. Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, 3615 Chestnut Street, #330, Philadelphia, 19104, Pennsylvania, USA

    Daniel Weintraub

  7. Parkinson's Disease and Mental Illness Research, Education and Clinical Centres (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Centre, 3900 Woodland Avenue, Philadelphia, 19104, Pennsylvania, USA

    Daniel Weintraub

Authors
  1. Dominic H. ffytche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Byron Creese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marios Politis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Ray Chaudhuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniel Weintraub
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Clive Ballard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dag Aarsland
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed equally to all aspects of manuscript preparation.

Corresponding author

Correspondence to Dominic H. ffytche.

Ethics declarations

Competing interests

K.R.C. has consulted and served on advisory boards for Britannia, AbbVie, Neuronova, Mundipharma and UCB, and has also served on advisory boards for Synapsus and Medtronic. He has received honoraria from Boehringer Ingelheim, GlaxoSmithKline, AbbVie, Britannia, UCB, Mundipharma, Otsuka and Zambon, and grants from Boehringer Ingelheim, GlaxoSmithKline, Britannia, AbbVie, UCB and Neuronova. He holds intellectual property rights for the KPP scale and the PDSS, and receives royalties for the books Non-Motor Symptoms of Parkinson's Disease and Fastfacts: Parkinson's Disease. C.B. declares grants and personal fees from Lundbeck and Acadia, and personal fees from Roche, Orion, GlaxoSmithKline, Otusaka, Heptares and Lilly. D.A. has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health, and serves as a paid consultant for H. Lundbeck and Axovant. The other authors declare no competing interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ffytche, D., Creese, B., Politis, M. et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol 13, 81–95 (2017). https://doi.org/10.1038/nrneurol.2016.200

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.200

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing